Research Nester released a report titled “Multiple Sclerosis Drugs and Treatment Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global multiple sclerosis drugs and treatment market in terms of market segmentation by drug, by route of administration, by distribution channel and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The market for multiple sclerosis drugs and treatment market is anticipated to record a significant CAGR of around 6% during the forecast period, i.e., 2019-2027. The market is segmented by drug, by route of administration, by distribution channel and by region, out of which, the route of administration segment is further bifurcated into oral and injection routes. The injection route of administration is estimated to hold the largest segment in the market on account of higher efficacy and better delivery of drug through the intravenous route. On the basis of drugs, the market is segmented into interferons, immunomodulators and immunosuppressants, out of which the immunomodulatory drugs are estimated to witness the highest market growth as a result of greater multiple sclerosis drugs being developed that have immunomodulatory properties.

Geographically, multiple sclerosis drugs and treatment market is anticipated to hold the largest share in the North America region. This can be attributed to the rising incidence of multiple sclerosis in the region. Additionally, growing research and development activities in the region are further estimated to support the market growth. The market in Europe is anticipated to hold the second largest share in the market on account of growing demand for improves therapeutic drugs and treatments for the disorder.

Rising Advancements in the Medical Industry to Drive the Market Growth

Expanding medical industry as a result of increased spending on healthcare is leading to various developments in the drugs that are available or being studied. The rising advancements in the healthcare industry can be attributed to the growing awareness among people for multiple sclerosis and the increasing requirement for effective drugs. However, the stringent government policies for the conduction of clinical studies of these drugs as well as the strict FDA approval are estimated to hamper the market growth during the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global multiple sclerosis drugs and treatment market which includes company profiling of Bayer AG (BAYN), Novartis AG (NOVN), Biogen (BIIB), Genzyme Corporation, F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., Pfizer Inc. (PFE), Merck KGaA (MRK), AbbVie Inc. and Opexa Therapeutics, Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global multiple sclerosis drugs and treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.